MOLN

Molecular Partners

MOLN

Market cap $137M

Overview Fund Activity

1 day

5 days

1 month

3 months

6 months

Year to date

1 year

5 years

10 years

About: Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Employees: 159

Healthcare Biotechnology

0

Funds holding %

of 7,469 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0.01% more ownership

Funds ownership: 8.87% [Q1] → 8.88% (+0.01%) [Q2]

0% more funds holding

Funds holding: 6 [Q1] → 6 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

3% less capital invested

Capital invested by funds: $14.2M [Q1] → $13.7M (-$445K) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$4

Avg. target

$4

High target

$4

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

JP Morgan

Richard Vosser

$4

Neutral

Maintained

3 Sep 2025

See Analyst Rankings

Financial journalist opinion

EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Tuesday.

EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced corporate highlights and unaudited financial results for the first half of 2025.

Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 22, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”) and Orano Med, a clinical-stage radiopharmaceutical company and a pioneer in the development of targeted alpha-particle therapies (TAT) with 212Pb (lead-212), today announced the debut of MP0726, its Radio-DARPin candidate targeting mesothelin (MSLN) and will present preclinical data in an oral presentation at the 2025 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), taking place June 21-24 in New Orleans, LA, USA.

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

Molecular Partners to cut workforce by a quarter

Swiss biotech firm Molecular Partners said on Tuesday that it plans to reduce its workforce by up to 40 positions, or around 24%, as part of a strategic review to boost operational efficiency and focus on key clinical assets.

Molecular Partners to cut workforce by a quarter

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announces that it has performed a strategic review of its current operations and headcount, with the objectives of increased efficiency in the organization and to sharpen the focus on advancing its clinical assets. As a result of this review the Company has informed the Amt für Wirtschaft of Kanton Zürich (Office for Economic Affairs) of its intention to reduce its current workforce by no more than 40 positions, representing a potential of ~24% of all positions.

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

Molecular Partners to Present at Upcoming Investor Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in two upcoming investor conferences.

Molecular Partners to Present at Upcoming Investor Conferences

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of three posters at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30 in Chicago, IL. The first poster includes positive Investigational New Drug (IND)-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb for small cell lung cancer patients. The second poster presents initial preclinical data on the second 212Pb-based Radio-DARPin, targeting mesothelin (MSLN) in solid tumors – both programs are co-developed with Orano Med. The third poster includes additional preclinical proof-of-concept data on the logic-gated CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors.

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that all motions proposed by the Board of Directors at the Annual General meeting were approved by the shareholders of the Company by a wide majority.

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

Zacks Investment Research

Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Molecular Partners AG Sponsored ADR (MOLN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher

Molecular Partners to hold three poster presentations at AACR 2025

Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212 Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer

Molecular Partners to hold three poster presentations at AACR 2025

See News Rankings

Charts implemented using Lightweight Charts™